SUNNYVALE, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today financial results for the fourth quarter and fiscal year 2010, ended June 30, 2010.
For the fourth quarter of fiscal 2010, Accuray reported total revenue of $61.8 million, a 5.1 percent increase over the fourth quarter of fiscal 2009 total revenue of $58.8 million. For the fiscal year ended June 30, 2010, total revenue was $221.6 million, a twelve million dollar decrease from the $233.6 million in total revenue recorded for fiscal year 2009.
Net income for the fourth quarter of fiscal 2010 was $5.0 million, or $0.08 per diluted share, compared to net income of $1.2 million, or $0.02 per diluted share, during the same period last year. Net income for fiscal year 2010 was $2.8 million or $0.05 per diluted share, compared to net income of $609,000 or $0.01 per diluted share for fiscal year 2009.
During the fourth quarter of fiscal 2010, 16 CyberKnife® Robotic Radiosurgery Systems were added to company backlog, with a total value of $74 million. In addition, new service and other ancillary orders with a value of $18 million were signed. During the fourth quarter, one order was canceled by a customer and removed from backlog.
Total backlog for the end of the fourth quarter of fiscal 2010 was $374 million, with approximately $132 million associated with CyberKnife System contracts and approximately $242 million associated with services and other recurring revenue.
In the fourth quarter of fiscal 2010, 10 new CyberKnife Systems were installed, making a full year installation total of 31 systems. At the end of the 2010 fiscal year, the worldwide CyberKnife installation base was 206.
"With 16 CyberKnife orders added into backlog, we are pleased to report another strong quarter of continued sales momentum, which has yielded 56 net orders for fiscal 2010," said Euan Thomson, president and chief executive officer of Accuray Incorporated. "Cancer patients worldwide are receiving highly precise, non-invasive, state-of-the-art radiosurgery treatment from an expanding base of installed CyberKnife Systems."
Accuray's cash and investment balances at the end of the fourth quarter of 2010 totaled $145.3 million, which includes cash and cash equivalents of $45.4 million, restricted cash of $22,000 and short-term investments of $99.9 million. Not included in the year-end cash and investments balance was $5.9 million, net, of in-transit cash associated with the liquidation of our auction-rate securities on June 30, 2010, which was received on July 1, 2010.
Outlook The following statement is forward-looking and actual results may differ materially. During fiscal year 2011 Accuray expects revenue to be in the range of $210 million to $225 million.
Additional InformationAdditional information regarding backlog segmentation, which will be discussed during the conference call, is available in the Investor Relations section of the company's Web site at www.accuray.com.
Earnings Call Open to Investors Accuray will hold a conference call for financial analysts and investors on Tuesday, August 31, 2010 at 2:00 p.m. PT / 5:00 p.m. ET. The conference call dial-in numbers are 1-866-578-5771 (USA) or 1-617-213-8055 (International), Conference ID: 28021423. A live webcast of the call will also be available from the Investor Relations section on the company's Web site at www.accuray.com. In addition, a recording of the call will be available by calling 1-888-286-8010 (USA) or 1-617-801-6888 (International), Conference ID number: 24002694, beginning at 5:00 p.m. PT / 8:00 p.m. ET, August 31, 2010 and will be available through September 3, 2010. A webcast replay will also be available from the Investor Relations section of the company's Web site at www.accuray.com from approximately 5:00 p.m. PT / 8:00 p.m. ET today through Accuray's release of its results for the first quarter of fiscal 2011, ending September 30, 2010.
About the CyberKnife® Robotic Radiosurgery SystemThe CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About AccurayAccuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 95,000 patients worldwide and currently more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor StatementThis press release contains forward-looking statements, including those concerning Accuray's expectations about revenue for fiscal year 2011, the portion of revenue attributable to CyberKnife System revenue, gross margin, profitability, customer installation schedules, realization of backlog and service activity. Forward looking statements involve risks and uncertainties that may lead to actual results varying materially from the forward looking statements. Accordingly, investors are cautioned not to place undue reliance on such statements. Many factors could cause actual performance or results to differ materially from these forward looking statements, including, but not limited to the uncertainties associated with the medical device industry; variability of installation and sales cycle including customer financing and construction delays; changes in the regulatory environment, including reimbursement for CyberKnife procedures; market acceptance of products; and the impact of competition. These and other risks are discussed under the heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information. Accuray IncorporatedUnaudited Condensed Consolidated Statements of Operations(in thousands, except per share data)Three months endedYears endedJune 30, 2010June 27, 2009June 30, 2010June 27, 2009Net revenue: Products
59,257Shared ownership program
2202409344,346Total net revenue
61,78858,803221,625233,598Cost of revenue: Cost of products
18,55919,01065,19768,904Cost of shared ownership program
1421211,019775Cost of services
11,87312,37750,73244,591Cost of other
1562056594,038Total cost of revenue
31,05827,090104,018115,290Operating expenses: Selling and marketing
8,2969,87034,18745,493Research and development
8,3739,18531,52335,992General and administrative
8,3937,71035,47236,223Total operating expenses
25,06226,765101,182117,708Income (loss) from operations
5,9963252,836(2,418)Interest and other income, net
(683)64613,082Income before provision for income taxes
5,3139712,837664Provision (benefit) for income taxes
9Net income per common share, basic and diluted:Basic
.01Weighted average common shares outstanding used in computing net income per
60,56459,32460,19158,729Cost of revenue, selling and marketing, research and development, and general
and administrative expenses include stock-based compensation charges as follows: Cost of revenue
2,285Selling and marketing
3,441Research and development
3,190General and administrative
,545Accuray IncorporatedUnaudited Condensed Consolidated Balance Sheets(in thousands, except share amounts) June 30, June 27, 20102009Assets Current assets: Cash and cash equivalents
$ 45,434$ 36,835Restricted cash
22527Short-term marketable securities
99,88164,634Accounts receivable, net of allowance for doubtful accounts of $115at June 30, 2010 and $484 at June 27, 2009
28,18628,909Prepaid expenses and other current assets
19,3566,186Deferred cost of revenue—current
7,88918,984Total current assets
238,723192,502Long-term marketable securities
-57,252Property and equipment, net
4,4954,495Intangible assets, net
388668Deferred cost of revenue—noncurrent
$263,184$274,386Liabilities and stockholders' equity Current liabilities: Accounts payable
$ 10,317$ 14,941Accrued expenses
42,01968,105Total current liabilities
86,675112,419Long-term liabilities: Long-term other liabilities
93,108120,484Stockholders' equity Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issuedand outstanding.
--Common stock, $0.001 par value; authorized: 100,000,000 shares; issued: 60,666,974
and 58,783,159 shares at June 30, 2010 and June 27, 2009, respectively; outstanding:
58,526,956 and 56,643,529 shares at June 30, 2010 and June 27, 2009, respectively.
5957Additional paid-in capital
287,764273,946Accumulated other comprehensive income (loss)
(117,676)(120,517)Total stockholders' equity
170,076153,902Total liabilities and stockholders' equity
$263,184$274,386Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D
|SOURCE Accuray Incorporated|
Copyright©2010 PR Newswire.
All rights reserved